Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207880 | 0.90 | KMT2A (0.49) | KMT2AMEN1ALDH1A1CYP2C9GBA1 | |
| SCHEMBL22404234 | 0.73 | CA12 (0.58) | KMT2AALDH1A1RBP4 | |
| SCHEMBL3195507 | 0.73 | HTT (0.51) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL5633219 | 0.70 | — | — | |
| SCHEMBL5126836 | 0.69 | CA1 (0.35) | ALDH1A1LMNA | |
| SCHEMBL22404274 | 0.68 | CA12 (0.55) | KMT2AALDH1A1RBP4 | |
| SCHEMBL6960982 | 0.68 | CA12 (0.55) | KMT2AALDH1A1RBP4 | |
| SCHEMBL217411 | 0.67 | — | — | |
| SCHEMBL4396576 | 0.67 | CYP2D6 (0.63) | KMT2AMEN1ALDH1A1TDP1CYP2D6 | |
| SCHEMBL4396572 | 0.67 | CYP2D6 (0.63) | KMT2AMEN1ALDH1A1TDP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | KMT2A 1809/4885MEN1 1234/4885ALDH1A1 421/4885 |
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | KMT2A 2787/4885MEN1 3927/4885ALDH1A1 212/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | KMT2A 2989/4885MEN1 3517/4885ALDH1A1 118/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | KMT2A 2787/4885MEN1 3927/4885ALDH1A1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.